SCHEMBL10150271

SCHEMBL10150271

OCC1CCCCN1c1nc(-c2ccncc2)nc2c1CCCC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 1/20 0.50
HIF1A Q16665 1/20 0.50
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
PRKCZ Q05513 6/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PRKCI P41743 5/20 0.40
GBA1 P04062 1/20 0.38
C5AR1 P21730 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150259 0.77 MEN1 (0.55) MAPTUSP2LMNATSHRPRKCZ
SCHEMBL10150266 0.76 LMNA (0.56) MAPTUSP2LMNATSHRPRKCZ
SCHEMBL20588673 0.73 CCNE2 (0.39) C5AR1TRPV1
SCHEMBL20588671 0.73 CCNE2 (0.39) C5AR1TRPV1
SCHEMBL20589585 0.73 CCNE2 (0.39) C5AR1TRPV1
SCHEMBL31095396 0.73 CCNE2 (0.39) C5AR1TRPV1
SCHEMBL29880508 0.73 CCNE2 (0.39) C5AR1TRPV1
SCHEMBL10150275 0.73 MEN1 (0.58) MAPTUSP2LMNATSHRPRKCZ
SCHEMBL20589134 0.72 CCNE2 (0.38) C5AR1TRPV1
SCHEMBL20589131 0.72 CCNE2 (0.38) C5AR1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 ALDH1A1 3086/4885MAPT 1627/4885HPGD 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.